株探米国株
英語
エドガーで原本を確認する
6-K 1 cybininc-form6xk06x11x2025.htm 6-K Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2025.
Commission File Number: 001-40673


Cybin Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.






SIGNATURE
CYBIN INC.
(Registrant)
 
Date: June 11, 2025 By:
/s/ Doug Drysdale    
Name: Doug Drysdale
Title: Chief Executive Officer




EXHIBIT INDEX
EX-99.1 2 a06-11x2025psychedelicscie.htm EX-99.1 Document

image_0.jpg



Cybin to Participate in the 2025 Psychedelic Science Conference

- Cybin CEO Doug Drysdale to participate in a panel discussion titled “The Home Stretch: Pivotal Trials and Preparing for Launch” on June 19, 2025 -

TORONTO, CANADA – June 11, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the Psychedelic Science 2025 Conference taking place June 16-20, 2025 in Denver, Colorado. The details are as follows:

Panel Title: The Home Stretch: Pivotal Trials and Preparing for Launch
Date and Time: Thursday, June 19, 2025 at 9:30 a.m. MDT (11:30 a.m. EDT)

“This annual gathering of global experts is a unique opportunity to share perspectives and engage with others on the forefront of achieving the potential of psychedelic therapeutics,” said Doug Drysdale, Chief Executive Officer of Cybin. “Cybin is fully committed to advancing our ongoing clinical work and delivering innovative alternatives to the current standard of care to address the large unmet medical need in treating mental health disorders. Recognition of this potential within medical circles has never been greater, and I am pleased to be part of the panel that is focused on these crucial next steps along the regulatory pathway.”

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.




Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Investor & Media Contact:  
Gabriel Fahel 
Chief Legal Officer 
Cybin Inc. 
1-866-292-4601 
irteam@cybin.com – or – media@cybin.com